149 related articles for article (PubMed ID: 38457597)
21. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
22. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
[TBL] [Abstract][Full Text] [Related]
23. A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion.
Shen YN; Bai XL; Jin G; Zhang Q; Lu JH; Qin RY; Yu RS; Pan Y; Chen Y; Sun PW; Guo CX; Li X; Ma T; Li GG; Gao SL; Lou JY; Que RS; Lau WY; Liang TB
HPB (Oxford); 2018 Nov; 20(11):1034-1043. PubMed ID: 29929784
[TBL] [Abstract][Full Text] [Related]
24. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
[TBL] [Abstract][Full Text] [Related]
25. Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma.
Rho SY; Lee SG; Park M; Lee J; Lee SH; Hwang HK; Lee MJ; Paik YK; Lee WJ; Kang CM
Sci Rep; 2019 Dec; 9(1):18634. PubMed ID: 31819109
[TBL] [Abstract][Full Text] [Related]
26. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
27. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors.
Kim N; Han IW; Ryu Y; Hwang DW; Heo JS; Choi DW; Shin SH
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935830
[TBL] [Abstract][Full Text] [Related]
28. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract][Full Text] [Related]
29. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
30. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.
Bae JS; Kim JH; Joo I; Chang W; Han JK
Eur Radiol; 2019 Jul; 29(7):3714-3724. PubMed ID: 30899975
[TBL] [Abstract][Full Text] [Related]
31. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
32. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
[TBL] [Abstract][Full Text] [Related]
34. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer.
Okabayashi T; Shima Y; Sumiyoshi T; Sui K; Iwata J; Morita S; Shimada Y; Iiyama T
Ann Surg Oncol; 2018 Jul; 25(7):1889-1895. PubMed ID: 29691738
[TBL] [Abstract][Full Text] [Related]
35. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
36. Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers.
Shimizu Y; Yamaue H; Maguchi H; Yamao K; Hirono S; Osanai M; Hijioka S; Kanemitsu Y; Sano T; Senda Y; Bhatia V; Yanagisawa A
Pancreas; 2015 Apr; 44(3):459-64. PubMed ID: 25423557
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy.
Qiao G; Ilagan CH; Fernandez-Del Castillo C; Ferrone CR; Janseen QP; Balachandran VP; Sell NM; Drebin JA; Hank T; Kingham TP; D'Angelica MI; Jarnagin WR; Lillemoe KD; Wei AC; Qadan M
Surgery; 2022 Oct; 172(4):1228-1235. PubMed ID: 35931556
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
[TBL] [Abstract][Full Text] [Related]
40. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
